植物血凝素样氧化型低密度脂蛋白受体介导氧化型低密度脂蛋白对内皮祖细胞存活和功能的影响

目的 研究植物血凝素样氧化型低密度脂蛋白受体（LOX—1）是否介导氧化型低密度脂蛋白（oxLDL）对内皮祖细胞（EPC）的存活及功能产生影响。方法 分选脐血CD34^＋细胞,培养于内皮细胞生长培养基（EGM-2）中。培养14d后,部分EPC与10、25、50μg/ml的oxLDL孵育48h;部分EPC先与LOX-1单克隆抗体（LOX—1mAb）预处理24h,再与50μg／ml oxLDL孵育48h;对照组不作处理。检测EPC存活率及EPC迁移、黏附和管状结构形成能力,并检测LOX-1的蛋白及mRNA表达。结果oxLDL浓度为25和50μg／ml时,凋亡率分别为（15．8±1．0）％和（18．8±2．0）％,显著高于对照组的（9．0±1．2）％（P〈0．05）;迁移率分别为（5．7±1．0）％和（5．1±0．8）％,显著低于对照组的（9．5±0．8）％,（P〈0．05）;黏附细胞数分别为（33±2）和（30±3）个,显著少于对照组的（37±5）个（P〈0．05）;形成的管状结构分别为（2．9±0．5）和（1．8±0．5）mm,显著短于对照组的（5．0±0．6）mm（P〈0．05）。OxLDL可增加LOX—1mRNA及蛋白的表达,oxLDL浓度为50μg／ml时,LOX—1mRNA表达由100％增加为（174±39）％,蛋白表达由100％增加为（172±8）％。OxLDL的上述作用能被LOX1mAb所阻断。结论OxLDL可降低EPC存活,抑制EPC功能,其作用是由LOX—1介导的。

Effects of oxidized low-density lipoprotein on endothelial progenitor cells survival and activity mediated by lectin-like oxidized low density lipoprotein receptor

OBJECTIVE: To investigate whether oxidized low-density lipoprotein (oxLDL) affects the survival and activity of endothelial progenitor cell (EPC) and whether the effects are mediated by lectin-like oxidized low-density lipoprotein receptor (LOX-1). METHODS: CD34+ cells isolated from human umbilical blood were cultured in endothelial cell growth medium-2 (EGM-2). After 14 days of culture, some EPCs were stimulated with 10, 25, 50 microg/ml of oxLDL for 48 hours; some were preincubated with LOX-1 mAb, a blocking antibody of LOX-1, for 24 hours, then exposed to 50 microg/ml oxLDL for 48 hours; others without any further treatment were used as control. The survival of EPC and the ability of adhesion, migration, and tube formation were examined. The levels of LOX-1 protein and mRNA expression were also assayed. RESULTS: Incubation with oxLDL at concentrations of 25 microg/ml or higher resulted in a dose-dependent increase of EPC apoptosis 25 microg/ml: (15.8 +/- 1.1.0%, 50 microg/ml: (18.8 +/- 2.0)% versus control: (9.0 +/- 1.2)%; P < 0.05]. Treated with oxLDL led to a significantly reduced migratry rate 25 microg/ml: (5.7 +/- 1.0)%, 50 microg/ml: (5.1 +/- 0.8)% versus control: (9.5 +/- 0.8)%; P < 0.05]. EPC treated with oxLDL showed a dose-dependent reduction of adhesion to fibronectin (25 Kg/ml: 33 +/- 2, 50 microg/ml: 30 +/- 3 versus control: 37 +/- 5; P < 0.05). Treatment with oxLDL impaired the in vitro vasculogenesis ability of EPCs. The total length of the tube structures in each photograph was decreased 25 microg/ml: (2.9 +/- 0.5) mm, 50 microg/ml: (1.8 +/- 0.5) mm versus control: (5.0 +/- 0.6) mm; P < 0.05]. The tube structure was severely disrupted, resulting in an incomplete and sparse tube network. However, all the detrimental effects on EPC were attenuated by pretreatment of EPC with LOX-1 mAb. In addition, Western blot analysis revealed that oxLDL increased LOX-1 protein expression from 100% to (172 +/- 8)% at a dose of 50 microg/ml. Furthermore, oxLDL caused an increase in LOX-1 mRNA expression from 100% to (174 +/- 39)% at a dose of 50 microig/ml. CONCLUSION: OxLDL can directly inhibit EPC survival and activity and these effects are mediated by its receptor, LOX-1.